Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Swedish Orphan Biovitrum Ab
(OP:
BIOVF
)
24.07
UNCHANGED
Last Price
Updated: 1:08 PM EDT, Aug 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Swedish Orphan Biovitrum Ab
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
August 08, 2024
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary...
Via
Benzinga
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
October 16, 2023
As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:
Via
Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
June 09, 2023
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t
Via
Benzinga
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
May 25, 2023
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
May 11, 2023
Investors are on the hunt for undervalued, underfollowed and emerging stocks and retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming.
Via
Benzinga
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
August 30, 2022
Via
Benzinga
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
July 08, 2022
Via
Benzinga
Why Shares of CTI BioPharma Are Soaring Wednesday
May 10, 2023
A buyout offer from Swedish Orphan Biovitrum drove up the stock's price.
Via
The Motley Fool
European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B
May 10, 2023
Swedish Orphan Biovitrum AB (OTC: BIOVF) has agreed to acquire CTI BioPharma (NASDAQ: CTIC) for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of
Via
Benzinga
Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year
March 21, 2023
Via
Benzinga
Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
November 10, 2022
Veru Inc.
Via
Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
November 04, 2022
Via
Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
July 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
July 11, 2022
Via
Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
July 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
March 09, 2022
Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001)...
Via
Benzinga
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
December 15, 2021
The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan...
Via
Benzinga
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
December 03, 2021
AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by...
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.